使用蒙特卡洛模拟对延长美罗培南给药时间进行药效学评价。
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
作者信息
Lomaestro Ben M, Drusano G L
机构信息
Albany Medical Center Hospital, 43 New Scotland Ave., Albany, NY 12208, USA.
出版信息
Antimicrob Agents Chemother. 2005 Jan;49(1):461-3. doi: 10.1128/AAC.49.1.461-463.2005.
Abstract
A Monte Carlo simulation demonstrated that 1 g of meropenem (MEM) every 8 h (q8h) (3-h infusion) has a higher target attainment rate against Pseudomonas aeruginosa than either 500 mg of MEM q8h (3-h infusion) or 0.5 g of imipenem-cilastatin (I-C) q6h (1-h infusion). For other pathogens, 500 mg of MEM q8h was equivalent or superior to I-C.
摘要
一项蒙特卡洛模拟表明，每8小时（q8h）静脉滴注1克美罗培南（MEM）（3小时输注）针对铜绿假单胞菌的目标达成率高于每8小时（q8h）静脉滴注500毫克MEM（3小时输注）或每6小时（q6h）静脉滴注0.5克亚胺培南-西司他丁（I-C）（1小时输注）。对于其他病原体，每8小时静脉滴注500毫克MEM等同于或优于I-C。
相似文献
1
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.使用蒙特卡洛模拟对延长美罗培南给药时间进行药效学评价。
Antimicrob Agents Chemother. 2005 Jan;49(1):461-3. doi: 10.1128/AAC.49.1.461-463.2005.
2
Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.β-内酰胺类抗生素用于继发性腹膜炎经验性治疗的药效学建模：来自OPTAMA项目的报告
Surg Infect (Larchmt). 2005 Fall;6(3):297-304. doi: 10.1089/sur.2005.6.297.
3
Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.蒙特卡洛模拟评估亚胺培南/西司他丁和美罗培南的 30 分钟和 3 小时输注方案。
Diagn Microbiol Infect Dis. 2010 Nov;68(3):251-8. doi: 10.1016/j.diagmicrobio.2010.06.012. Epub 2010 Sep 18.
4
Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.亚胺培南-西司他丁、美罗培南和哌拉西林-他唑巴坦用于皮肤和软组织感染经验性治疗的药效学建模：OPTAMA项目报告
Surg Infect (Larchmt). 2005 Winter;6(4):419-26. doi: 10.1089/sur.2005.6.419.
5
Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.基于匈牙利医院收集的针对铜绿假单胞菌的药效学靶点达成情况优化抗生素给药方案。
Int J Antimicrob Agents. 2006 Nov;28(5):433-8. doi: 10.1016/j.ijantimicag.2006.07.014.
6
Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.使用蒙特卡洛模拟设计美罗培南的优化药效学给药策略。
J Clin Pharmacol. 2003 Oct;43(10):1116-23. doi: 10.1177/0091270003257225.
7
When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.当药效优于成本时：一个抗菌药物管理项目选择最佳抗菌药物的方法。
Clin Ther. 2013 Jun;35(6):766-71. doi: 10.1016/j.clinthera.2013.05.004.
8
Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.使用蒙特卡罗模拟评估β-内酰胺类药物对儿童铜绿假单胞菌感染的药效学：OPTAMA项目报告
Clin Ther. 2005 Nov;27(11):1820-30. doi: 10.1016/j.clinthera.2005.11.007.
9
Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.成人医院获得性肺炎经验性治疗中，标准和延长输注抗生素方案的药效学目标达标概率。
Clin Ther. 2009 Nov;31(11):2765-78. doi: 10.1016/j.clinthera.2009.11.026.
10
Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.多利培南、亚胺培南和美罗培南对亚太地区主要革兰氏阴性菌的药效学特征分析。
Int J Antimicrob Agents. 2013 Jan;41(1):47-51. doi: 10.1016/j.ijantimicag.2012.09.007. Epub 2012 Nov 3.
引用本文的文献
1
Antibiotics in Necrotizing Soft Tissue Infections.坏死性软组织感染中的抗生素
Antibiotics (Basel). 2021 Sep 13;10(9):1104. doi: 10.3390/antibiotics10091104.
2
Interplay between Meropenem and Human Serum Albumin on Expression of Carbapenem Resistance Genes and Natural Competence in Acinetobacter baumannii.美罗培南与人类血清白蛋白对鲍曼不动杆菌碳青霉烯耐药基因表达及自然感受态的相互作用
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0101921. doi: 10.1128/AAC.01019-21. Epub 2021 Jul 19.
3
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients.优化重症患者的抗菌药物给药方案
Microorganisms. 2021 Jun 28;9(7):1401. doi: 10.3390/microorganisms9071401.
4
Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.美罗培南在早产儿和足月儿体内的生理药代动力学模型研究。
Clin Pharmacokinet. 2021 Dec;60(12):1591-1604. doi: 10.1007/s40262-021-01046-6. Epub 2021 Jun 22.
5
Dosage Regimens for Meropenem in Children with Pseudomonas Infections Do Not Meet Serum Concentration Targets.儿童铜绿假单胞菌感染的美罗培南剂量方案不符合血清浓度目标。
Clin Transl Sci. 2020 Mar;13(2):301-308. doi: 10.1111/cts.12710. Epub 2019 Nov 20.
6
Integrated pharmacokinetic-pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections.整合药代动力学-药效学模型以评估血流感染中经验性碳青霉烯类治疗。
Infect Drug Resist. 2018 Sep 27;11:1591-1596. doi: 10.2147/IDR.S168191. eCollection 2018.
7
Meropenem Assessment before and after Implementation of a Small-Dose, Short-Interval Standard Dosing Regimen.小剂量、短间隔标准给药方案实施前后的美罗培南评估
Can J Hosp Pharm. 2018 Jan-Feb;71(1):14-21. Epub 2018 Mar 7.
8
Augmented Renal Clearance in Critically Ill Patients: A Systematic Review.危重症患者的增强肾脏清除率：系统评价。
Clin Pharmacokinet. 2018 Sep;57(9):1107-1121. doi: 10.1007/s40262-018-0636-7.
9
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.不动杆菌感染的临床与病理生理学概述：一个世纪的挑战
Clin Microbiol Rev. 2017 Jan;30(1):409-447. doi: 10.1128/CMR.00058-16.
10
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.重症患者美罗培南的群体药代动力学及达标概率
Eur J Clin Pharmacol. 2016 Jul;72(7):839-48. doi: 10.1007/s00228-016-2053-x. Epub 2016 Apr 6.
本文引用的文献
1
Prevention of resistance: a goal for dose selection for antimicrobial agents.预防耐药性：抗菌药物剂量选择的一个目标。
Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S42-50. doi: 10.1086/344653.
2
Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection.一名双肺移植患者感染多重耐药铜绿假单胞菌后的持续β-内酰胺类抗生素治疗
Transplantation. 2001 Mar 27;71(6):744-5. doi: 10.1097/00007890-200103270-00009.
3
Continuous infusion versus intermittent administration of meropenem in critically ill patients.美罗培南持续输注与间歇给药用于重症患者的比较
J Antimicrob Chemother. 1999 Apr;43(4):523-7. doi: 10.1093/jac/43.4.523.
4
The pharmacodynamics of beta-lactams.β-内酰胺类药物的药效学
Clin Infect Dis. 1998 Jul;27(1):10-22. doi: 10.1086/514622.
5
Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.碳青霉烯类抗生素持续给药与间歇给药在体外动态模型中的抗菌效果
Antimicrob Agents Chemother. 1997 Jun;41(6):1215-9. doi: 10.1128/AAC.41.6.1215.
6
Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions.抗菌效果与浓度-时间曲线下面积之间的关系作为比较抗生素给药方式的基础：美罗培南静脉推注与持续输注
Antimicrob Agents Chemother. 1997 Feb;41(2):352-6. doi: 10.1128/AAC.41.2.352.
7
The pharmacokinetics of meropenem.美罗培南的药代动力学。
Scand J Infect Dis Suppl. 1995;96:11-6.
8
Multiple-dose pharmacokinetics of imipenem-cilastatin.亚胺培南-西司他丁的多剂量药代动力学。
Antimicrob Agents Chemother. 1984 Nov;26(5):715-21. doi: 10.1128/AAC.26.5.715.
Zotero 插件